home / stock / tpst / tpst quote
Last: | $2.11 |
---|---|
Change Percent: | 0.0% |
Open: | $2.12 |
Close: | $2.11 |
High: | $2.16 |
Low: | $2.1 |
Volume: | 390,611 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.11 | $2.12 | $2.11 | $2.16 | $2.1 | 390,611 | 07-04-2024 |
$2.11 | $2.12 | $2.11 | $2.16 | $2.1 | 390,054 | 07-03-2024 |
$2.12 | $2.13 | $2.12 | $2.185 | $2.08 | 544,439 | 07-02-2024 |
$2.14 | $2.15 | $2.14 | $2.18 | $2.08 | 583,202 | 07-01-2024 |
$2.19 | $2.18 | $2.19 | $2.25 | $2.14 | 841,412 | 06-28-2024 |
$2.17 | $2.16 | $2.17 | $2.29 | $2.12 | 1,007,813 | 06-27-2024 |
$2.16 | $1.99 | $2.16 | $2.2099 | $1.98 | 1,411,626 | 06-26-2024 |
$2.06 | $2.1 | $2.06 | $2.13 | $2 | 855,637 | 06-25-2024 |
$2.09 | $2.04 | $2.09 | $2.13 | $1.9 | 1,631,020 | 06-24-2024 |
$2.03 | $1.96 | $2.03 | $2.11 | $1.87 | 2,775,543 | 06-21-2024 |
$2.01 | $2.68 | $2.01 | $2.71 | $1.9 | 30,784,277 | 06-20-2024 |
$2.85 | $2.92 | $2.85 | $3 | $2.83 | 939,311 | 06-19-2024 |
$2.85 | $2.92 | $2.85 | $3 | $2.83 | 939,311 | 06-18-2024 |
$2.91 | $2.88 | $2.91 | $2.91 | $2.67 | 447,258 | 06-17-2024 |
$2.9 | $3.1 | $2.9 | $3.1 | $2.84 | 569,225 | 06-14-2024 |
$3.03 | $3.08 | $3.03 | $3.12 | $3.03 | 179,117 | 06-13-2024 |
$3.09 | $3.14 | $3.09 | $3.18 | $3.025 | 244,696 | 06-12-2024 |
$3.11 | $3.16 | $3.11 | $3.16 | $3.03 | 284,103 | 06-11-2024 |
$3.17 | $3.09 | $3.17 | $3.19 | $3.01 | 326,682 | 06-10-2024 |
$3.11 | $3.16 | $3.11 | $3.24 | $3.05 | 516,077 | 06-07-2024 |
News, Short Squeeze, Breakout and More Instantly...
Tempest Therapeutics Inc. Company Name:
TPST Stock Symbol:
NASDAQ Market:
Tempest Therapeutics Inc. Website:
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
21 months median OS in amezalpat arm vs. 15 in control arm 50% (20/40) of patients on amezalpat arm remain in survival follow up 0.65 hazard ratio, maintained since 0.59 observed in primary analysis 10 months earlier Early and persistent separation of survival curves ...
BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today announced the company plans to report new data from the global ran...